Silence Therapeutics is a biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines created with proprietary siRNA technology. SLN124 is our wholly owned siRNA in clinical development to potentially address a range of hematological conditions through its ability to modulate hepcidin, the body's master iron regulator. SLN124 is being evaluated in a phase 1 study in thalassemia and a phase 1/2 study in polycythemia vera. For more information, please visit https://www.silence-therapeutics.com/.